Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.95 USD | +0.75% | -7.76% | -25.00% |
May. 28 | Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia | CI |
May. 23 | Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call |
Financials (USD)
Sales 2024 * | 111M | Sales 2025 * | 170M | Capitalization | 2.85B |
---|---|---|---|---|---|
Net income 2024 * | -360M | Net income 2025 * | -319M | EV / Sales 2024 * | 22.9 x |
Net cash position 2024 * | 305M | Net cash position 2025 * | 157M | EV / Sales 2025 * | 15.9 x |
P/E ratio 2024 * |
-7.31
x | P/E ratio 2025 * |
-8.52
x | Employees | 525 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.52% |
Latest transcript on Arrowhead Pharmaceuticals, Inc.
1 day | +0.75% | ||
1 week | -7.76% | ||
1 month | +1.46% | ||
3 months | -28.50% | ||
6 months | +8.25% | ||
Current year | -25.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 07-11-30 | |
Director of Finance/CFO | 57 | 08-12-31 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 10-11-22 |
Michael Perry
BRD | Director/Board Member | 64 | 11-12-18 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.40% | 0 M€ | 0.00% | - | |
0.35% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 22.95 | +0.75% | 1,047,062 |
24-05-30 | 22.78 | -0.39% | 1,297,890 |
24-05-29 | 22.87 | -4.39% | 1,038,916 |
24-05-28 | 23.92 | -3.86% | 945,370 |
24-05-24 | 24.88 | +0.85% | 561,959 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.00% | 2.85B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ARWR Stock